Brief: Amylyx Pharmaceuticals Q1 EPS USD -0.42 Vs. IBES Estimate USD -0.47
08/05/2025 12:00
May 08 (Reuters) - Amylyx Pharmaceuticals Q1 operating expenses USD 37.803 million. Q1 operating income USD -37.803 million vs. IBES estimate USD -41.1 million Q1 pretax profit USD -35.907 million Q1 net income USD -35.907 million vs. IBES estimate USD -38.5 million
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock